HER2 positive breast carcinoma

Researchers are testing whether adding an experimental drug called HLX22 to standard trastuzumab and chemotherapy helps people with locally advanced or metastatic HER2-positive breast cancer that has already been treated with a HER2 ADC. About 90 adults will receive either HLX22 …

This study offers continued access to tucatinib, an oral targeted therapy, for people with HER2-positive cancers (including breast, cervical, and lung) who were already benefiting from the drug in a previous Pfizer-sponsored trial. The main goal is to monitor long-term safety and…

This phase 2 trial is investigating whether an experimental drug called SHR-A1811, given alone or followed by a standard combination therapy (THPy), can improve outcomes for women with stage II-III HER2-positive breast cancer before they undergo surgery. Participants first receiv…

This trial is testing whether adding azeliragon, a RAGE inhibitor, to the drug T-DXd can help people with HER2-positive or HER2-low metastatic breast cancer whose cancer has progressed despite prior T-DXd treatment. The study will first find the safest dose of the combination, th…

This trial tests whether adding an immunotherapy drug called retifanlimab to two standard HER2-targeted therapies (trastuzumab and pertuzumab) can improve treatment response in people with HER2-positive breast cancer. The main goal is to see if the combination leads to a complete…

This phase 2 trial is testing a two-step treatment approach for people with advanced HER2-positive breast cancer. First, participants receive an induction therapy with trastuzumab rezetecan. If the disease does not progress, they then move to a maintenance phase combining trastuz…

This phase 3 trial is testing whether giving four cycles of chemotherapy combined with targeted therapy (trastuzumab and pertuzumab) before surgery works as well as the standard six cycles for people with intermediate-risk HER2-positive breast cancer. The goal is to see if a shor…

This phase II trial is testing an experimental drug called SMP-656 in people with HER2-positive breast cancer that has spread or cannot be removed and has worsened after prior treatment with a specific type of antibody-drug conjugate. The study aims to see if SMP-656 can shrink t…

This trial tests a planned sequence of treatments for people with advanced or metastatic HER2-positive and hormone receptor-positive breast cancer. Participants first receive T-DXd (Enhertu) plus pertuzumab, then switch to a maintenance combination of palbociclib, endocrine thera…

This study tests whether adding a new oral drug called fulvestaciclib to standard anti-HER2 and hormone therapy can help people with HR+/HER2+ advanced breast cancer live longer without their disease getting worse. Some participants receive the combo after initial chemotherapy, w…

This study is testing whether some people with early-stage breast cancer can safely skip surgery after chemotherapy and instead use only radiation. It includes 84 adults with HER2-positive or triple-negative breast cancer who have responded well to initial chemo. The goal is to s…

This study tests a drug called SHR-A1811 in 60 adults with HER2-positive advanced breast cancer who have had up to 2 prior treatments. Researchers want to see if giving the drug in different ways (like injection or infusion) can shrink tumors. The main goal is to measure how many…

This study tests whether a new drug, trastuzumab rezetecan, works as well as or better than the current drug trastuzumab deruxtecan for women with advanced HER2-positive breast cancer that has worsened after previous treatment. About 100 women will be randomly assigned to one of …

This phase III trial is for people with HER2-positive stage IV breast cancer that has spread to a limited number of spots (oligometastatic). It tests whether adding surgery and focused radiation to standard drug therapy helps them live longer or delays cancer growth compared to d…

This study tests whether a new biosimilar drug, HLX319, works as well as the approved drug Phesgo for people with HER2-positive early or locally advanced breast cancer. About 258 participants will receive either the biosimilar or the original drug before surgery to compare how th…

This study tests whether adding 4 cycles of the targeted drug trastuzumab rezetecan (T-DXh) can eliminate residual cancer in HER2-positive breast cancer patients who still have disease after standard chemotherapy. About 59 adults will receive the drug before surgery. The main goa…

This study tests a combination of targeted drugs (trastuzumab and pertuzumab) plus a low-dose chemotherapy (vinorelbine) given before surgery to elderly patients (70+) with HER2-positive breast cancer. The goal is to see if this approach can completely eliminate cancer cells in t…

This Phase 2 trial tests a new combination of drugs—paclitaxel polymer micelles, trastuzumab, pertuzumab, and adebelimab—against the standard taxane-based regimen for people with advanced HER2-positive breast cancer. About 140 participants will be randomly assigned to one of the …

This study tests a new combination of drugs (PLD, cyclophosphamide, trastuzumab, and pertuzumab) for people with HER2-positive early breast cancer who still have cancer after initial treatment. The goal is to see if this combo can increase the rate of complete remission before su…

This phase 2 study tests whether a new drug called JSKN003 works better than the current standard therapy for people with HER2-positive breast cancer that has returned or spread. About 60 adults who have not had prior treatment for advanced disease will receive either JSKN003 or …

This study tests a new combination of drugs (zanidatamab, tucatinib, and chemotherapy) in people with advanced HER2-positive breast cancer that cannot be removed by surgery or has spread. The goal is to find the safest dose and see if the treatment shrinks tumors. About 24 adults…

This study tests whether a special PET scan (HER2-PET) can help doctors personalize treatment for early-stage HER2-positive breast cancer. After two cycles of standard therapy, the scan results will determine if patients need stronger or milder treatment. The goal is to improve t…

This study tests a personalized approach for people with HER2-positive breast cancer. After two cycles of standard therapy, those whose tumors shrink less than 40% will switch to a new drug combination (SHR-A1811 plus pertuzumab) for four more cycles before surgery. The goal is t…

This study will follow 500 people with HER2-positive advanced breast cancer who are starting treatment with pyrotinib, a daily oral targeted therapy. Researchers want to see how well the drug controls the cancer and what side effects occur in everyday medical practice, not just i…

This study looks at whether adding pyrotinib to two standard drugs (trastuzumab and pertuzumab) can help control HER2-positive advanced breast cancer longer. About 42 adults with advanced disease will receive this combination as maintenance therapy after initial treatment. The ma…

This study tests a new approach for women with a common type of early breast cancer (HR+/HER2-). Instead of standard chemotherapy before surgery, some participants will receive a combination of hormone therapy and a targeted drug (abemaciclib) based on their tumor's gene test res…

This early-phase trial tests whether combining the targeted drug trastuzumab deruxtecan (T-DXd) with precise radiation (SRS) is safe for people with HER2-positive breast cancer that has spread to the brain. Up to 20 participants will receive the drug by IV every three weeks along…

This phase 2 trial tests whether a new drug, trastuzumab-rezetecan, works as well as the established drug T-DXd in shrinking HER2-positive breast tumors before surgery. About 68 women with early or locally advanced breast cancer will receive one of the two drugs for 8 cycles, the…

This study compares a new drug, SHR-A1811, with a standard combination therapy (pyrotinib plus capecitabine) in 100 adults with advanced HER2-positive breast cancer that did not respond to the first-line treatment trastuzumab. The goal is to see which approach better delays cance…

This study looks at two powerful drugs, sacituzumab govitecan (SG) and trastuzumab deruxtecan (T-DXd), for people with a certain type of advanced breast cancer (HER2-low/TROP2-high). The goal is to find out which drug works best when given first and how to switch if the first sto…

This study tests whether a drug called RC48, combined with chemotherapy, works better than standard treatments for women with advanced HER2-positive breast cancer whose disease has progressed after prior therapy. About 268 participants will be randomly assigned to receive either …

This study tests a new drug combination (SHR-A1811 plus pertuzumab) given before surgery to women with early or locally advanced HR-positive, HER2-positive breast cancer. The goal is to see if this treatment can eliminate all cancer cells in the breast and lymph nodes by the time…

This study tests whether a new drug combination (HLX87 plus HLX22 or pertuzumab) works better than standard chemotherapy before surgery for people with HER2-positive early or locally advanced breast cancer. About 817 participants will be randomly assigned to one of three treatmen…

This phase 2 trial tests whether adding an experimental immunotherapy (QL1706) to standard chemotherapy and targeted drugs can better eliminate HER2-positive breast cancer before surgery. About 188 people with early or locally advanced disease will be randomly assigned to receive…

This phase 2 trial tests whether adding the drug inavolisib to a standard pre-surgery regimen (pertuzumab, trastuzumab, and nab-paclitaxel) can improve outcomes for people with a specific genetic mutation (PIK3CA) in HER2-positive early breast cancer. About 164 participants will …

This phase III trial tests a personalized approach for HER2-positive breast cancer, where treatment is adjusted based on early response (ctDNA and imaging). The goal is to reduce chemotherapy side effects without compromising effectiveness. The study will enroll 2000 women with e…

This study tracks 600 adults in Korea with advanced HER2-positive breast cancer who are starting TUKYSA for the first time. Researchers will monitor how well the drug works and any side effects in real-world settings, outside of controlled trials. The goal is to confirm the drug'…

This study tests special radioactive drugs that can both find and treat solid tumors that have spread to the brain. Ten adults with advanced breast cancer and active brain metastases will receive a single dose of a diagnostic agent to see if it lights up the brain tumors on a sca…

This study tests whether herombopag tablets can prevent low platelet counts in 45 women with HER2-positive breast cancer who are receiving T-DM1 therapy. T-DM1 is effective but often causes low platelets, especially in Asian patients, which can force treatment delays or dose redu…

This early-stage trial tests whether combining trastuzumab (a targeted antibody) with specially engineered immune cells (CAR T-cells) can safely control HER2-positive advanced breast cancer and other solid tumors. About 36 adults will receive the combination after a short chemoth…

This phase II trial tests whether a maintenance therapy of trastuzumab plus either pyrotinib or dalpiciclib and endocrine therapy can delay disease progression in people with HER2-positive advanced breast cancer. After an initial treatment with trastuzumab rezetecan, 288 particip…

This study tests a drug called SHR-A1811 in 51 women with HER2-positive breast cancer that has spread to the brain or the lining of the brain and spinal cord. The drug is given either through a vein or directly into the spinal fluid. The goal is to see if it is safe and can shrin…

This Phase II trial tests whether adding neratinib to the standard drug trastuzumab deruxtecan works better than trastuzumab deruxtecan alone for HER2-positive breast cancer that has spread to the brain and cannot be removed by surgery. About 202 women aged 18-70 will be randomly…

This study tests whether a new MRI contrast agent, gadopiclenol, can detect brain metastases earlier than standard methods in 180 patients with advanced lung, breast, or skin cancer. Participants will receive screening brain MRIs to compare diagnosis timing and accuracy. The goal…

This study compares two ways of giving a large-volume subcutaneous injection of targeted therapy (pertuzumab and trastuzumab) to 40 women with HER2-positive breast cancer. Each patient will receive one injection by a nurse using a stopwatch to mimic a steady speed, and another in…

This study is developing an AI tool that analyzes tumor images, proteins, and patient data to predict whether a person with advanced HER2-positive or low-expression breast cancer will benefit from the targeted drug T-DXd. The goal is to avoid giving ineffective treatment, which c…

This study looks at whether tracking tumor DNA in the blood (ctDNA) can help doctors see how well breast cancer treatment is working before surgery. It will include 186 people with stage II-III HER2-positive or triple-negative breast cancer. Researchers will take blood samples at…

This study will review medical records of about 240 adults in Kazakhstan with HER2-positive metastatic breast cancer to see how they were treated and how well they did. Researchers will look at treatments given in routine care (except one specific drug) and track outcomes like ho…

This study looks back at medical records of 2000 women with HER2-positive early breast cancer who still had cancer after initial treatment. Researchers want to see which follow-up drug regimen—trastuzumab plus pertuzumab or T-DM1—leads to better long-term outcomes. The goal is to…

This study looks at 150 breast cancer patients starting T-DXd, a drug that often causes nausea, vomiting, and weight loss. Researchers will measure blood levels of a hormone called GDF-15 before and during treatment to see if changes in GDF-15 are linked to these side effects. If…

This study will track gut microbiome changes in 12 women with hormone receptor-positive breast cancer starting Verzenio (abemaciclib) therapy. Participants will take either a resistant potato starch supplement or a placebo, and provide stool samples and symptom questionnaires rem…

This study will enroll over 1,000 women with HER2-positive breast cancer to analyze the molecular characteristics and subtypes of their tumors. Participants will receive standard pre-surgery treatment with trastuzumab, pertuzumab, and chemotherapy. The goal is to identify which s…